Cancer Immunology, Immunotherapy (2018) 67:507–511 https://doi.org/10.1007/s00262-018-2122-3 ACKNO WLEDGEMENT TO RE VIE WERS © Springer-Verlag GmbH Germany, part of Springer Nature 2018 The Editors-in-Chief thank the following ad hoc reviewers and our Editorial Board for evaluating manuscripts submitted to Cancer Immunology, Immunotherapy in 2017. We are committed to the publication of research that advances the field of tumor immunology and immunotherapy and rely on our many reviewers to ensure that papers accepted by the journal adhere to all aspects of good scientific and ethical practice and have significant scientific merit. We very much appreciate the voluntary unremunerated provision of their expertise and time by our reviewers, and recognize that their constructive comments and recommendations are essential contributions promoting the overall quality of Cancer Immunology, Immu- notherapy and the scientific record. Aarntzen, Erik Azuma, Miyuki Bordron, Anne Abken, Hinrich Bosch, Jacobus Abrams, Scott Baba, Hideo Bosch-Voskens, Caroline Adema, Gosse Baban, Babak Brandau, Sven Adler, Frederick Bagarazzi, Mark Breckpot, Karine Adotevi, Olivier Bagley, Stephen Breitbach, Caroline Adusumilli, Prasad Bajor, David Briançon-Marjollet, Anne Aerts, Joachim Balachandran, Vinod Bright, Robert Akasaki, Yasuharu Baldanzi, Gianluca Brossart, Peter Alain, Tommy Ball, Edward Brownell, Isaac Albelda, Steven Banham, Alison Brudvik, Kristoffer Alici, Evren Barbuto, Jose Alexandre
Cancer Immunology, Immunotherapy – Springer Journals
Published: Feb 7, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera